Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 537

1.

[Effects of сramizol on expression of the ApoA1 gene in rats with experimental hyperlipidemia].

Lizunov AV, Okunevich IV, Orlov SV, Lebedev AA, Bychkov ER, Piotrovskiy LB, Shabanov PD.

Biomed Khim. 2019 Aug;65(5):403-406. doi: 10.18097/PBMC20196505403. Russian.

PMID:
31666413
2.

A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin alfa for Chemotherapy-Induced Anemia in Patients With Advanced Non-Small Cell Lung Cancer.

Gascón P, Nagarkar R, Šmakal M, Syrigos KN, Barrios CH, Sánchez JC, Zhang L, Henry DH, Gordon D, Hirsh V, Kubota K, Orlov S, Thomas G, Steinmetz T, Kang JH, Tomita DK, Fleishman AN, Park JK, De Oliveira Brandao C.

J Thorac Oncol. 2019 Oct 16. pii: S1556-0864(19)33563-4. doi: 10.1016/j.jtho.2019.10.005. [Epub ahead of print]

3.

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.

Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris V, Calvo Ferrandiz A, Tarpgaard LS, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Christy-Bittel J, Anderson L, Sandor V, Tabernero J.

N Engl J Med. 2019 Oct 24;381(17):1632-1643. doi: 10.1056/NEJMoa1908075. Epub 2019 Sep 30.

PMID:
31566309
4.

Transcriptomic changes triggered by ouabain in rat cerebellum granule cells: Role of α3- and α1-Na+,K+-ATPase-mediated signaling.

Smolyaninova LV, Shiyan AA, Kapilevich LV, Lopachev AV, Fedorova TN, Klementieva TS, Moskovtsev AA, Kubatiev AA, Orlov SN.

PLoS One. 2019 Sep 26;14(9):e0222767. doi: 10.1371/journal.pone.0222767. eCollection 2019.

5.

Elevation of Intracellular Na+ Contributes to Expression of Early Response Genes Triggered by Endothelial Cell Shrinkage.

Shiyan AA, Sidorenko SV, Fedorov D, Klimanova EA, Smolyaninova LV, Kapilevich LV, Grygorczyk R, Orlov SN.

Cell Physiol Biochem. 2019;53(4):638-647. doi: 10.33594/000000162.

6.

[The evaluation of efficiency of rehabilitation activities concerning the disabled in the Russian Federation].

Gorenkov RV, Efimova AO, Orlov SA, Rozalieva YY, Petiukova ON, Kuzyakina AS.

Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med. 2019 Jul;27(4):418-423. doi: 10.32687/0869-866X-2019-27-4-418-423. Russian.

PMID:
31465658
7.

An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer.

Morgensztern D, Karaseva N, Felip E, Delgado I, Burdaeva O, Dómine M, Lara P, Paik PK, Lassen U, Orlov S, Trigo J, Shomova M, Baker-Neblett K, Vasquez J, Wang X, Yan L, Mitrica I, DeYoung MP, Garrido P.

Lung Cancer. 2019 Oct;136:74-79. doi: 10.1016/j.lungcan.2019.08.011. Epub 2019 Aug 14.

PMID:
31446228
8.

Anti-fibrotic effects of tannic acid through regulation of a sustained TGF-beta receptor signaling.

Reed EB, Ard S, La J, Park CY, Culligan L, Fredberg JJ, Smolyaninova LV, Orlov SN, Chen B, Guzy R, Mutlu GM, Dulin NO.

Respir Res. 2019 Jul 29;20(1):168. doi: 10.1186/s12931-019-1141-8.

9.

Hypoxia as a Factor Involved in the Regulation of the apoA-1, ABCA1, and Complement C3 Gene Expression in Human Macrophages.

Bogomolova AM, Shavva VS, Nikitin AA, Nekrasova EV, Dizhe EB, Larionova EE, Kudriavtsev IV, Orlov SV.

Biochemistry (Mosc). 2019 May;84(5):529-539. doi: 10.1134/S0006297919050079.

PMID:
31234767
10.

Preface.

Orlov SN.

Curr Top Membr. 2019;83:xv-xvii. doi: 10.1016/S1063-5823(19)30024-9. No abstract available.

PMID:
31196612
11.

Control of lung myofibroblast transformation by monovalent ion transporters.

Dulin NO, Smolyaninova LV, Orlov SN.

Curr Top Membr. 2019;83:15-43. doi: 10.1016/bs.ctm.2019.01.002. Epub 2019 Feb 14.

PMID:
31196603
12.

Ubiquitous and cell type-specific transcriptomic changes triggered by dissipation of monovalent cation gradients in rodent cells: Physiological and pathophysiological implications.

Klimanova EA, Sidorenko SV, Smolyaninova LV, Kapilevich LV, Gusakova SV, Lopina OD, Orlov SN.

Curr Top Membr. 2019;83:107-149. doi: 10.1016/bs.ctm.2019.01.006. Epub 2019 Feb 22.

PMID:
31196602
13.

[Characterization of Distal and Proximal Alternative Promoters of the Human ApoA-I Gene].

Mogilenko DA, Shavva VS, Dizhe EB, Orlov SV.

Mol Biol (Mosk). 2019 May-Jun;53(3):485-496. doi: 10.1134/S0026898419030121. Russian.

14.

Overall Survival of Patients With ALK-Positive Metastatic Non-Small-Cell Lung Cancer in the Russian Federation: Nationwide Cohort Study.

Tsimafeyeu I, Moiseenko F, Orlov S, Filippova E, Belonogov A, Nebesnykh A, Khalimov A, Karabina E, Shikina V, Abdelgafur A, Statsenko G, Titova I, Isaichikov D, Makarnyaeva G, Mordovskiy A, Barkovskaya O, Smirnov A, Gikalo M, Savelov N, Kosov D, Imyanitov E, Demidova I, Tjulandin S.

J Glob Oncol. 2019 May;5:1-7. doi: 10.1200/JGO.19.00024.

15.

A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma.

van Brummelen EMJ, Levchenko E, Dómine M, Fennell DA, Kindler HL, Viteri S, Gadgeel S, López PG, Kostorov V, Morgensztern D, Orlov S, Zauderer MG, Vansteenkiste JF, Baker-Neblett K, Vasquez J, Wang X, Bellovin DI, Schellens JHM, Yan L, Mitrica I, DeYoung MP, Trigo J.

Invest New Drugs. 2019 May 7. doi: 10.1007/s10637-019-00783-7. [Epub ahead of print]

PMID:
31065954
16.

Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study.

Cho BC, Obermannova R, Bearz A, McKeage M, Kim DW, Batra U, Borra G, Orlov S, Kim SW, Geater SL, Postmus PE, Laurie SA, Park K, Yang CT, Ardizzoni A, Bettini AC, de Castro G Jr, Kiertsman F, Chen Z, Lau YY, Viraswami-Appanna K, Passos VQ, Dziadziuszko R.

J Thorac Oncol. 2019 Jul;14(7):1255-1265. doi: 10.1016/j.jtho.2019.03.002. Epub 2019 Mar 7.

17.

Prognostic Factors in Early-stage NSCLC: Analysis of the Placebo Group in the MAGRIT Study.

Cho BC, DE Pas T, Kalofonos H, Wang Q, Ramlau R, Cheng Y, Vitiello F, Laisaar T, Vallières E, Kubisa B, Orlov S, Park K, Debruyne C, Vansteenkiste J.

Anticancer Res. 2019 Mar;39(3):1403-1409. doi: 10.21873/anticanres.13255.

PMID:
30842175
18.

Sustained Smad2 Phosphorylation Is Required for Myofibroblast Transformation in Response to TGF-β.

Ard S, Reed EB, Smolyaninova LV, Orlov SN, Mutlu GM, Guzy RD, Dulin NO.

Am J Respir Cell Mol Biol. 2019 Mar;60(3):367-369. doi: 10.1165/rcmb.2018-0252LE. No abstract available.

PMID:
30821500
19.

[The Concept of Patient-Oriented Model of Organization of Medical Care].

Khalfin RA, Madiyanova VV, Stolbov AP, Svistunov AA, Orlov SA, Bakulina AA, Efimova AO, Tatarinova TA, Gil AY.

Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med. 2018 Nov;26(6):418-423. doi: 10.32687/0869-866X-2018-26-6-418-423. Russian.

PMID:
30748135
20.

Development of a motor and somatosensory evoked potentials-guided spinal cord Injury model in non-human primates.

Baklaushev VP, Durov OV, Kim SV, Gulaev EV, Gubskiy IL, Konoplyannikov MA, Zabozlaev FG, Zhang C, Agrba VZ, Orlov SV, Lapin BA, Troitskiy AV, Averyanov AV, Ahlfors JE.

J Neurosci Methods. 2019 Jan 1;311:200-214. doi: 10.1016/j.jneumeth.2018.10.030. Epub 2018 Oct 25.

PMID:
30393204
21.

Transcriptomic changes in C2C12 myotubes triggered by electrical stimulation: Role of Ca2+i-mediated and Ca2+i-independent signaling and elevated [Na+]i/[K+]i ratio.

Sidorenko S, Klimanova E, Milovanova K, Lopina OD, Kapilevich LV, Chibalin AV, Orlov SN.

Cell Calcium. 2018 Dec;76:72-86. doi: 10.1016/j.ceca.2018.09.007. Epub 2018 Sep 30.

PMID:
30300758
22.

Search for Upstream Cell Volume Sensors: The Role of Plasma Membrane and Cytoplasmic Hydrogel.

Orlov SN, Shiyan A, Boudreault F, Ponomarchuk O, Grygorczyk R.

Curr Top Membr. 2018;81:53-82. doi: 10.1016/bs.ctm.2018.07.001. Epub 2018 Aug 9.

PMID:
30243440
23.

EGFR T790M Mutation in TKI-Naïve Clinical Samples: Frequency, Tissue Mosaicism, Predictive Value and Awareness on Artifacts.

Lavdovskaia ED, Iyevleva AG, Sokolenko AP, Mitiushkina NV, Preobrazhenskaya EV, Tiurin VI, Ivantsov AO, Bizin IV, Stelmakh LV, Moiseyenko FV, Karaseva NA, Orlov SV, Moiseyenko VM, Korzhenevskaya MA, Zaitsev IA, Kozak AR, Chistyakov IV, Akopov AL, Volkov NM, Togo AV, Imyanitov EN.

Oncol Res Treat. 2018;41(10):634-642. doi: 10.1159/000491441. Epub 2018 Aug 27.

24.

Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.

Buttigliero C, Shepherd FA, Barlesi F, Schwartz B, Orlov S, Favaretto AG, Santoro A, Hirsh V, Ramlau R, Blackler AR, Roder J, Spigel D, Novello S, Akerley W, Scagliotti GV.

Oncologist. 2019 Jun;24(6):e251-e259. doi: 10.1634/theoncologist.2018-0089. Epub 2018 Aug 23.

PMID:
30139835
25.

Variability in lung cancer response to ALK inhibitors cannot be explained by the diversity of ALK fusion variants.

Mitiushkina NV, Tiurin VI, Iyevleva AG, Kholmatov MM, Filippova EA, Moiseyenko FV, Levchenko NE, Sardaryan IS, Odintsova SV, Lozhkina AM, Volkov NM, Karaseva NA, Moiseyenko VM, Orlov SV, Imyanitov EN.

Biochimie. 2018 Nov;154:19-24. doi: 10.1016/j.biochi.2018.07.018. Epub 2018 Jul 30.

PMID:
30071258
26.

Proteomics-based identification of hypoxia-sensitive membrane-bound proteins in rat erythrocytes.

Sidorenko SV, Ziganshin RH, Luneva OG, Deev LI, Alekseeva NV, Maksimov GV, Grygorczyk R, Orlov SN.

J Proteomics. 2018 Jul 30;184:25-33. doi: 10.1016/j.jprot.2018.06.008. Epub 2018 Jun 18. No abstract available.

PMID:
29929038
27.

In Vivo Experimental Study of Biological Compatibility of Tissue Engineered Tracheal Construct in Laboratory Primates.

Gilevich IV, Sotnichenko AS, Karal-Ogly DD, Gubareva EA, Kuevda EV, Polyakov IS, Lapin BA, Orlov SV, Porkhanov VA, Chekhonin VP.

Bull Exp Biol Med. 2018 Apr;164(6):770-774. doi: 10.1007/s10517-018-4077-y. Epub 2018 Apr 16.

PMID:
29658077
28.

Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials.

Wu YL, Sequist LV, Tan EH, Geater SL, Orlov S, Zhang L, Lee KH, Tsai CM, Kato T, Barrios CH, Schuler M, Hirsh V, Yamamoto N, O'Byrne K, Boyer M, Mok T, Peil B, Märten A, Chih-Hsin Yang J, Paz-Ares L, Park K.

Clin Lung Cancer. 2018 Jul;19(4):e465-e479. doi: 10.1016/j.cllc.2018.03.009. Epub 2018 Mar 17.

29.

In vitro assessment of electrospun polyamide-6 scaffolds for esophageal tissue engineering.

Zhuravleva M, Gilazieva Z, Grigoriev TE, Shepelev AD, Kh Tenchurin T, Kamyshinsky R, Krasheninnikov SV, Orlov S, Caralogli G, Archipova S, Holterman MJ, Mavlikeev M, Deev RV, Chvalun SN, Macchiarini P.

J Biomed Mater Res B Appl Biomater. 2019 Feb;107(2):253-268. doi: 10.1002/jbm.b.34116. Epub 2018 Mar 30.

PMID:
29603873
30.

Insulin downregulates C3 gene expression in human HepG2 cells through activation of PPARγ.

Shavva VS, Bogomolova AM, Efremov AM, Trofimov AN, Nikitin AA, Babina AV, Nekrasova EV, Dizhe EB, Oleinikova GN, Missyul BV, Orlov SV.

Eur J Cell Biol. 2018 Apr;97(3):204-215. doi: 10.1016/j.ejcb.2018.03.001. Epub 2018 Mar 9.

PMID:
29550264
31.

Tumor necrosis factor α stimulates endogenous apolipoprotein A-I expression and secretion by human monocytes and macrophages: role of MAP-kinases, NF-κB, and nuclear receptors PPARα and LXRs.

Shavva VS, Mogilenko DA, Nekrasova EV, Trulioff AS, Kudriavtsev IV, Larionova EE, Babina AV, Dizhe EB, Missyul BV, Orlov SV.

Mol Cell Biochem. 2018 Nov;448(1-2):211-223. doi: 10.1007/s11010-018-3327-7. Epub 2018 Feb 13.

PMID:
29442267
32.

Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study.

Gambacorti-Passerini C, Orlov S, Zhang L, Braiteh F, Huang H, Esaki T, Horibe K, Ahn JS, Beck JT, Edenfield WJ, Shi Y, Taylor M, Tamura K, Van Tine BA, Wu SJ, Paolini J, Selaru P, Kim TM.

Am J Hematol. 2018 May;93(5):607-614. doi: 10.1002/ajh.25043. Epub 2018 Feb 8.

33.

Effects of Hypoxia on Erythrocyte Membrane Properties-Implications for Intravascular Hemolysis and Purinergic Control of Blood Flow.

Grygorczyk R, Orlov SN.

Front Physiol. 2017 Dec 22;8:1110. doi: 10.3389/fphys.2017.01110. eCollection 2017. Review.

34.

Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study.

Scagliotti GV, Shuster D, Orlov S, von Pawel J, Shepherd FA, Ross JS, Wang Q, Schwartz B, Akerley W.

J Thorac Oncol. 2018 Jun;13(6):849-854. doi: 10.1016/j.jtho.2017.12.009. Epub 2017 Dec 27.

35.

Vasoconstriction triggered by hydrogen sulfide: Evidence for Na+,K+,2Cl-cotransport and L-type Ca2+ channel-mediated pathway.

Orlov SN, Gusakova SV, Smaglii LV, Koltsova SV, Sidorenko SV.

Biochem Biophys Rep. 2017 Nov 6;12:220-227. doi: 10.1016/j.bbrep.2017.09.010. eCollection 2017 Dec.

36.

Augmented gene expression triggered by Na+,K+-ATPase inhibition: Role of Ca2+i-mediated and -independent excitation-transcription coupling.

Smolyaninova LV, Koltsova SV, Sidorenko SV, Orlov SN.

Cell Calcium. 2017 Dec;68:5-13. doi: 10.1016/j.ceca.2017.10.002. Epub 2017 Oct 9.

PMID:
29129208
37.

Electrical pulse stimulation decreases electrochemical Na+ and K+ gradients in C2C12 myotubes.

Danilov K, Sidorenko S, Milovanova K, Klimanova E, Kapilevich LV, Orlov SN.

Biochem Biophys Res Commun. 2017 Nov 18;493(2):875-878. doi: 10.1016/j.bbrc.2017.09.133. Epub 2017 Sep 25.

PMID:
28958945
38.

Enzyme kinetics of cellulose hydrolysis of Miscanthus and oat hulls.

Makarova EI, Budaeva VV, Kukhlenko AA, Orlov SE.

3 Biotech. 2017 Oct;7(5):317. doi: 10.1007/s13205-017-0964-6. Epub 2017 Sep 14.

39.

Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors.

Ponomarenko DM, Klimova ID, Chapygina YA, Dvornichenko VV, Zhukova NV, Orlova RV, Manikhas GM, Zyryanov AV, Burkhanova LA, Badrtdinova II, Oshchepkov BN, Filippova EV, Orlov SV, Kolesnikov SI, Sufianov AA, Baum SR, Zaitzeva OY, Komissarov AB, Grudinin MP, Kiselev OI, Tsyb AF, Venanzi F, Shcherbinina V, Chursov A, Gabai VL, Shneider AM.

Oncotarget. 2017 Mar 25;8(32):53730-53739. doi: 10.18632/oncotarget.16574. eCollection 2017 Aug 8.

40.

Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study.

Gottfried M, Bennouna J, Bondarenko I, Douillard JY, Heigener DF, Krzakowski M, Mellemgaard A, Novello S, Orlov S, Summers Y, von Pawel J, Stöhr J, Kaiser R, Reck M.

Target Oncol. 2017 Aug;12(4):475-485. doi: 10.1007/s11523-017-0517-2.

PMID:
28702806
41.

Na+,K+-ATPase as a Target for Treatment of Tissue Fibrosis.

Orlov SN, La J, Smolyaninova LV, Dulin NO.

Curr Med Chem. 2019;26(3):564-575. doi: 10.2174/0929867324666170619105407. Review.

PMID:
28625151
42.

A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer.

Glisson B, Besse B, Dols MC, Dubey S, Schupp M, Jain R, Jiang Y, Menon H, Nackaerts K, Orlov S, Paz-Ares L, Ramlau R, Tang R, Zhang Y, Zhu M.

Clin Lung Cancer. 2017 Nov;18(6):615-625.e8. doi: 10.1016/j.cllc.2017.05.007. Epub 2017 May 10.

PMID:
28601388
43.

Level of Interleukins IL-6 and IL-15 in Blood Plasma of Mice after Forced Swimming Test.

Kapilevich LV, Kironenko TA, Zakharova AN, Kabachkova AV, Orlov SN.

Bull Exp Biol Med. 2017 May;163(1):10-13. doi: 10.1007/s10517-017-3725-y. Epub 2017 Jun 3.

PMID:
28577104
44.

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.

Jänne PA, van den Heuvel MM, Barlesi F, Cobo M, Mazieres J, Crinò L, Orlov S, Blackhall F, Wolf J, Garrido P, Poltoratskiy A, Mariani G, Ghiorghiu D, Kilgour E, Smith P, Kohlmann A, Carlile DJ, Lawrence D, Bowen K, Vansteenkiste J.

JAMA. 2017 May 9;317(18):1844-1853. doi: 10.1001/jama.2017.3438.

45.

Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer.

Reck M, Blais N, Juhasz E, Gorbunova V, Jones CM, Urban L, Orlov S, Barlesi F, Kio E, Keilholz U, Qin Q, Qian J, Nickner C, Dziubinski J, Xiong H, Mittapalli RK, Dunbar M, Ansell P, He L, McKee M, Giranda V, Ramalingam SS.

J Thorac Oncol. 2017 Jul;12(7):1098-1108. doi: 10.1016/j.jtho.2017.04.010. Epub 2017 Apr 29.

46.

Na⁺i,K⁺i-Dependent and -Independent Signaling Triggered by Cardiotonic Steroids: Facts and Artifacts.

Orlov SN, Klimanova EA, Tverskoi AM, Vladychenskaya EA, Smolyaninova LV, Lopina OD.

Molecules. 2017 Apr 14;22(4). pii: E635. doi: 10.3390/molecules22040635. Review.

47.

Time- and dose dependent actions of cardiotonic steroids on transcriptome and intracellular content of Na+ and K+: a comparative analysis.

Klimanova EA, Tverskoi AM, Koltsova SV, Sidorenko SV, Lopina OD, Tremblay J, Hamet P, Kapilevich LV, Orlov SN.

Sci Rep. 2017 Mar 27;7:45403. doi: 10.1038/srep45403.

48.

Promoting resource stewardship: Reducing inappropriate free thyroid hormone testing.

Gilmour JA, Weisman A, Orlov S, Goldberg RJ, Goldberg A, Baranek H, Mukerji G.

J Eval Clin Pract. 2017 Jun;23(3):670-675. doi: 10.1111/jep.12698. Epub 2017 Mar 14.

PMID:
28295871
49.

Control of Myofibroblast Differentiation and Function by Cytoskeletal Signaling.

Sandbo N, Smolyaninova LV, Orlov SN, Dulin NO.

Biochemistry (Mosc). 2016 Dec;81(13):1698-1708. doi: 10.1134/S0006297916130071. Review.

50.

Dynamic and Static Exercises Differentially Affect Plasma Cytokine Content in Elite Endurance- and Strength-Trained Athletes and Untrained Volunteers.

Kapilevich LV, Zakharova AN, Kabachkova AV, Kironenko TA, Orlov SN.

Front Physiol. 2017 Jan 30;8:35. doi: 10.3389/fphys.2017.00035. eCollection 2017.

Supplemental Content

Support Center